An off-the-shelf use of DNAJB1-PRKACA-based neoepitopes for immunotherapeutic cancer approaches is possible, because translation of the DNAJB1-PRKACA fusion results in a defined and unique protein in contrast to other fusion transcripts (36, 67–69). This evidence concerns the gene PRKACA and cancer.